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Abstract
Background
AU
Multiple
: Pleaseconfirmthatallheadinglevelsarerepresentedcorrectly:
Coronavirus Disease 2019 (COVID-19) vaccines appear to be safe and efficacious,
but only high-income countries have the resources to procure sufficient vaccine doses for
most of their eligible populations. The World Health Organization has published guidelines
for vaccine prioritisation, but most vaccine impact projections have focused on high-income
countries, and few incorporate economic considerations. To address this evidence gap, we
projected the health and economic impact of different vaccination scenarios in Sindh Province, Pakistan (population: 48 million).

Methods and findings
We fitted a compartmental transmission model to COVID-19 cases and deaths in Sindh
from 30 April to 15 September 2020. We then projected cases, deaths, and hospitalisation
outcomes over 10 years under different vaccine scenarios. Finally, we combined these projections with a detailed economic model to estimate incremental costs (from healthcare and
partial societal perspectives), disability-adjusted life years (DALYs), and incremental costeffectiveness ratio (ICER) for each scenario.
We project that 1 year of vaccine distribution, at delivery rates consistent with COVAX
projections, using an infection-blocking vaccine at $3/dose with 70% efficacy and 2.5-year
duration of protection is likely to avert around 0.9 (95% credible interval (CrI): 0.9, 1.0) million cases, 10.1 (95% CrI: 10.1, 10.3) thousand deaths, and 70.1 (95% CrI: 69.9, 70.6)
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thousand DALYs, with an ICER of $27.9 per DALY averted from the health system perspective. Under a broad range of alternative scenarios, we find that initially prioritising the older
(65+) population generally prevents more deaths. However, unprioritised distribution has
almost the same cost-effectiveness when considering all outcomes, and both prioritised and
unprioritised programmes can be cost-effective for low per-dose costs. High vaccine prices
($10/dose), however, may not be cost-effective, depending on the specifics of vaccine performance, distribution programme, and future pandemic trends.
The principal drivers of the health outcomes are the fitted values for the overall transmission scaling parameter and disease natural history parameters from other studies, particularly age-specific probabilities of infection and symptomatic disease, as well as social
contact rates. Other parameters are investigated in sensitivity analyses.
This study is limited by model approximations, available data, and future uncertainty.
Because the model is a single-population compartmental model, detailed impacts of nonpharmaceutical interventions (NPIs) such as household isolation cannot be practically represented or evaluated in combination with vaccine programmes. Similarly, the model cannot
consider prioritising groups like healthcare or other essential workers. The model is only fitted to the reported case and death data, which are incomplete and not disaggregated by,
e.g., age. Finally, because the future impact and implementation cost of NPIs are uncertain,
how these would interact with vaccination remains an open question.

Conclusions

Competing interests: The authors have declared
that no competing interests exist.

COVID-19 vaccination can have a considerable health impact and is likely to be cost-effective if more optimistic vaccine scenarios apply. Preventing severe disease is an important
Abbreviations: AU
CEPI,: Anabbreviationlisthasbeencompiledforthoseusedthroughoutthetext:Pleaseverifythatallentriesarecorrect:
Coalition for Epidemic
contributor to this impact. However, the advantage of prioritising older, high-risk populations
Preparedness Innovations; COVID-19, Coronavirus
is smaller in generally younger populations. This reduction is especially true in populations
Disease 2019; CrI, credible interval; DALY,
with more past transmission, and if the vaccine is likely to further impede transmission rather
disability-adjusted life year; DIC, deviance
than just disease. Those conditions are typical of many low- and middle-income countries.
information criterion; EPI, Expanded Program on
Immunization; GDP, gross domestic product;
ICER, incremental cost-effectiveness ratio; LMIC,
low- and middle-income country; NPI,
nonpharmaceutical intervention; QALY, qualityadjusted life year; SAGE, Strategic Group of Experts
on Immunization; SARS-CoV-2, Severe Acute
Respiratory Syndrome Coronavirus 2; WHO, World
Health Organization; YLL, year of life lost.

Author summary
Why was this study done?
• The evidence base for health and economic impact of Coronavirus Disease 2019
(COVID-19) vaccination in low- and middle-income settings is limited.
• Searching PubMed, medRxiv, and econLit using the search term (“coronavirus” OR
“covid” OR “ncov”) AND (“vaccination” OR “immunisation”) AND (“model” OR
“cost” OR “economic”) for full text articles published in any language between 1 January
2020 and 20 January 2021, returned 29 (PubMed), 1,167 (medRxiv), and 0 (econLit)
studies: 20 overall were relevant, with only 4 exclusively focused on low- or middleincome countries (India, China, Mexico), while 3 multicountry analyses also included
low- or middle-income settings.
• However, only 3 of these studies are considered economic outcomes, all of them comparing the costs of vaccination to the costs of nonpharmaceutical interventions (NPIs)
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and concluding that both are necessary to reduce infections and maximise economic
benefit.
• The majority of studies focus on high-income settings and conclude that prioritizing
COVID-19 vaccination to older age groups is the preferred strategy to minimise mortality, particularly when vaccine supplies are constrained, while other age- or occupational
risk groups should be prioritised when vaccine availability increases or when other policy objectives are pursued.

What did the researchers do and find?
• We combined epidemiological and economic analysis of COVID-19 vaccination based
on real-world disease and programmatic information in the Sindh Province of Pakistan.
• We found that vaccination in this setting is likely to be highly cost-effective, and even
cost saving, as long as the vaccine is reasonably priced and efficacy is high.
• Unlike studies in high-income settings, we also found that vaccination programmes targeting all adults may have almost as much benefit as those initially targeted at older populations, likely reflecting the higher previous infection rates and different demography
in these settings.

What do these findings mean?
• The results suggest that low- and middle-income countries (LMICs) see less benefit to
initially prioritising vaccination of older (65+) populations compared to unprioritised
distribution. Factors outside this analysis, like cost differences between prioritised and
unprioritised programmes, will further influence the preferred approach.
• As such, LMICs and international bodies providing guidance for LMICs need to consider evidence specific to these settings when making recommendations about COVID19 vaccination.
• Further data and model-based analyses in such settings are urgently needed in order to
ensure that vaccination decisions are appropriate to these contexts.

Introduction

The Coronavirus Disease 2019 (COVID-19) pandemic AU
has resulted
: Pleaseconfirmthattheedittothesentenceinthe
in over 50 million cases
and nearly 2 million deaths in 2020, with cases in nearly every country [1]. To reduce transmission of the causal Severe Acute Respiratory Syndrome Coronavirus 2 (SARSAU
-CoV-2)
: PleasenotethatSARS
virus,
many countries have imposed physical distancing measures such as closure of schools and
workplaces and restrictions on public gatherings [2]. Such measures often incur socioeconomic costs that are not indefinitely sustainable, particularly in resource-poor settings [3],
and, when these measures are lifted, transmission has readily resumed in most places [4].
Vaccination may provide a durable option to protect individuals. If a vaccine also reduces
transmission (e.g., by preventing infection or limiting infectiousness of disease), even unvaccinated individuals would have reduced infection risk. As of January 2021, 3 vaccines have
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completed Phase III trials, and at least 20 other vaccine candidates were in Phase III trials, with
over 250 in earlier trials or preclinical studies [5,6].
Many high-income and large middle-income countries have signed bilateral agreements with
manufacturers, preordering enough vaccines to cover their populations, some multiple times [7].
The World Health Organization (WHO), Gavi, the Vaccine Alliance, and the Coalition for Epidemic
Preparedness Innovations (CEPI) launched the COVAX Facility to enable many small and lowerincome countries to pool their purchasing power. To date, 141 countries and territories have started
the COVAX participation process, which will distribute vaccines to participating countries according
to population size [8,9]. This distribution will cover a small proportion (3%) of those populations in
the months following vaccine approval, aiming to expand to 20% by the end of 2021 [10]. Given that
this supply may not be sufficient, countries may need to purchase additional vaccines, and to do so
need to be able to quantify the costs and benefits of various vaccination programmes to compare to
other health sector investments. Additionally, countries face other substantial health sector resource
constraints that may require external funding including scale-up of vaccine delivery infrastructure
and workforce and continued care and treatment of those with COVID-19.
WHO’s Strategic Group of Experts on Immunization (SAGE) has issued a roadmap to help
countries prioritise distribution of these limited doses. This roadmap draws from work across
multiple disciplines, including modelling to project the health outcomes, health sector financing, and broader economic consequences of different vaccine prioritisation strategies, but
much of the available research has focused on high-income settings [11–14].
To address this gap, we assessed the health impact, economic impact, and cost-effectiveness
of COVID-19 vaccination in Sindh Province, Pakistan, using a combined epidemiological and
economic model. We chose a specific setting to ensure that our model could incorporate local
mobility and cost data. Sindh Province initially confirmed a large number of cases, followed by
declining incidence after a nationwide lockdown. Our analysis addresses vaccine prioritisation
questions faced by both global (WHO) and national (Pakistan Ministry of Health) decisionmakers and illustrates the decision support analysis that should be applied more broadly in
low- and middle-income countries (LMICs).

Methods
Ethics
All clinical data used were obtained from publicly available sources, so no ethical approval was
required for this study.

Epidemiological model
To capture the natural history and transmission of SARS-CoV-2, we used a previously published compartmental model [15–17] tailored to the population of Sindh using population
data from WorldPop [18] and assumed baseline population contact rates from previously estimated national patterns for Pakistan [19].
Briefly, the model compartments are an extended SEIRS+V (Susceptible, Exposed, Infectious with multiple subcompartments, Recovered and/or Vaccinated, potentially converting
either to Susceptible or if in the combined state to only Recovered or Vaccinated) system with
births, deaths, and age structure. For all compartments other than Recovered and/or Vaccinated, we use event-time distributions derived from global observations (Table 1). For Recovered and/or Vaccinated, we consider multiple characteristic protection durations, given the
uncertainty in these durations. For the Recovered compartment (with and without vaccination), we assume perfect protection; we address the Vaccinated compartment protection along
with the vaccination programme details in the “Vaccine programme” section. The modelled
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Table 1. Summary of epidemiological, vaccine, and economic parameters used in the base case and scenario analysis.
Parameter

Base case value

Scenario range

Source

Epidemiological parameters
Latent period

Gamma(mean = 2.5, k = 5)

[41,42]

Contact rates

Age-dependent synthetic contact matrix for Pakistan

[19]

Proportion asymptomatic

age-specific

posterior from [15]

Duration of infectiousness

Gamma(mean = 5, k = 4)

[41,42]

Duration of natural immunity

2.5 years

1 year, lifelong

Assumed

Vaccine-related parameters
Duration of vaccine programme

1 year

5 and 10 years

Initial age targeting

65+

15+

Duration of vaccine-induced
immunity

2.5 years

1 year, lifelong

Assumed

Initial number of courses
administered per day

4,000 (based on COVAX availability; see S1 Text)

8,000, 12,000, 184,000 (short
campaign only)

[25]

Number of doses per course

2

1

[25]

Efficacy

70%

30%, 90%

Assumed

Vaccine procurement price per
dose

$3

$6 and $10

[8]

Wastage

15% of vaccine procurement price per dose, 10% of
immunisation supplies procurement price per dose

[36]; see S1 Text for details

Freight

10% of vaccine procurement price per dose

Assumed

Syringes and safety boxes

0.04

UNICEF supply division price
list

Cold chain costs per dose
(national level)

$0.133

[37]

Economic parameters

Cold chain costs per dose (service $0.029
level)

Microcosting. Various sources
(see S1 Text).

Human resource per dose

$0.38

Microcosting from DCP
project [38,39]

Transport per dose

Transport to facility: $0.04 Transport from facility to campaign
site: $0.001

Microcosting. Various sources
(see S1 Text).

Social mobilisation per dose

$0.16

[40]

Health system markup

31% of cost per dose excluding procurement price per dose,
immunisation supplies, wastage, and freight

[37]

Perspective

Health system

Societal

Discount rate

3% costs, 3% DALYs

3% costs, 0% DALYs

[35]

US dollars abbreviated as $ and disability-adjusted life years as DALYs.
https://doi.org/10.1371/journal.pmed.1003815.t001

loss of protection can represent a range of phenomena, from antibody waning to shifts in the
circulating pathogen with time leading to immune escape.
We assumed that contact patterns changed over the course of the epidemic, and estimated
these changes using Google Community Mobility indicators [20] for Sindh and school closures
as reflected in the Oxford Coronavirus Government Response Tracker [2]. For projections, we
assume that contact patterns return to the baseline contract matrix at the end of May 2021,
and no further physical distancing interventions are imposed.

Model fitting and projections
Using Bayesian inference via Markov Chain Monte Carlo, we fit 5 elements of the model: the
effective introduction date, t0, as number of days after 1 January 2020; the basic reproduction
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Fig 1. Outcomes for fitted model ascertained outcomes compared to data. Sample ascertained trajectories (n = 250)
from the posterior of model parameters (blue) compared to observed outcomes (black). For observed cases and deaths,
the solid line is the 7-day average, with points corresponding to daily reports. For the limited serological data, the
crosshairs show the collection period and binomial confidence interval on the seropositivity estimates. The serial study
results with expected low seropositivity are faded. Expected duration of infection-derived immunity assumed to be 2.5
years; other immunity assumptions in Fig C in S1 Text. All of the assumptions considered produce comparable fits to
reported cases and deaths through September 2020.
https://doi.org/10.1371/journal.pmed.1003815.g001

number in Sindh without any interventions, R0; a time-varying ascertainment rate for both
COVID-19 deaths and cases; and the standard deviation characterising the distribution of
reported data points around the model-predicted mean value. We fitted the model to the new
daily cases and deaths in Sindh reported by the Government of Pakistan COVID-19 Dashboard [21] from 30 April to 14 September 2020 (Fig 1A and 1B).
As a validation, we compared model outputs to 3 reports of SARS-CoV-2 seroprevalence
(Fig 1C), all from Karachi [22–24]. Two concerned broad population samples over an
extended period [23,24]: These generally overlap with model estimates but are aggregated over
time making precise comparison difficult. The third conducted repeat surveys in 2 specific
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regions [22], finding clear qualitative trends that match model trends—limited exposure preMay, rapid rise through July, and subsequent plateau—but recorded lower levels. Additional
figures in that study, however, indicate that the specific study sites recorded lower positivity
trends generally than their broader districts, and particularly during the case surge in June,
suggesting that the measured values may be lower than those in the broader population. As
another out-of-sample validation, we also compared forward projections to Sindh data for 15
September 2020 to 15 January 2021.
Since the waning rate of infection-acquired immunity is unknown and the benefits of vaccination highly sensitive to this parameter, we repeated the fitting exercise with 4 assumptions
for waning of infection-acquired immunity: lifelong and exponentially waning immunity with
expected durations of 1, 2.5, and 5 years.

Vaccine programme
We assumed vaccination distribution consistent with the availability of doses indicated by
WHO SAGE’s Working Group on COVID-19 Vaccines [25]. We assumed that vaccination
required 2 doses per course, since this is true of most vaccines in the COVAX portfolio.
The number of full courses available each month was assumed to be divided among all
COVAX participating countries proportional to population, and likewise for subnational
regions. Additionally, we assumed that 15% of courses would be wasted for reasons such as
cold chain failures, incorrect use, or failure to complete second doses (which we pessimistically
assume means lack of vaccine protection). Hence, we assumed that Sindh would complete
4,000 courses/day in the first 3 months (with a 30-day delay accounting for timing of second
dose) after a vaccine is approved. We assumed that courses delivered would increase to 16,000,
24,000, then 32,000 in subsequent quarters using the schedule suggested by WHO SAGE [25]
modified to reflect the current vaccine landscape (see Section E in S1 Text). For sensitivity
analyses, we also consider (a) a constant 4,000 courses per day and (b) a sufficient constant
rate to cover the eligible population in 6 months, 184k courses per day, which is comparable to
peak rates achieved in some high-income countries (around 0.4% of the population per day).
For primary vaccine scenarios, we assumed that the vaccine is infection-blocking and that
protection is complete for some individuals and absent in others (i.e., “all-or-nothing” protection); we considered other vaccine models (every exposure tests the efficacy independently, i.e.,
“leaky” protection, and/or disease-only blocking) as sensitivity studies. Vaccine doses are distributed among individuals in the Susceptible and Recovered compartments; Susceptible individuals become Vaccinated, and Recovered individuals become Recovered and Vaccinated.
We considered different durations of protection: Once vaccinated in the model, individuals
lose vaccine protection with an exponentially distributed duration. Finally, we considered different efficacy levels of protection. A wide variety of COVID-19 vaccines are available to Pakistan via COVAX, which have reported different efficacy levels [26]. Instead of modelling a
particular vaccine, for our base case scenario, we assume a vaccine with 70% efficacy that protects for 2.5 years on average. As alternatives, we considered a higher efficacy (90%) or longer
duration of protection (5 years). See S1 Text for more combinations.
We track vaccine impact for 10 years and assume that vaccination continues at the same
rate (after initial scale-up) for 1 (base case), 5 or 10 years, or for 0.5 year for the sensitivity
study of high delivery rate. For simplicity, during the time the vaccine programme is active,
vaccination occurs on each day of the week, rather than excluding weekends and holidays. We
assume that vaccination cost does not fundamentally change as the programme continues and
coverage increases; this implicitly assumes a linear average in the costs of vaccination across
groups and time.
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Given the emphasis on prioritising older adults in WHO’s vaccine prioritisation roadmap
[27], we considered 2 scenarios for distribution: either individuals 15+ years old for the duration or individuals 65+ years old for the first two-quarters of the first year before shifting to 15
+. For all scenarios, we assume that vaccine doses are uniformly (i.e., proportional to fraction
of population) distributed in the targeted populations.

Health and economic outcomes
We modelled the impact of COVID-19 vaccination on cases, deaths, and disability-adjusted
life years (DALYs) compared to counterfactual scenarios with no vaccination over a 10-year
time horizon. For different vaccination scenarios, the averted DALYs were combined with the
costs of the vaccination programme and any reduction in COVID-19 case management costs
from vaccination to calculate incremental cost-effectiveness ratios (ICERs). Our analysis followed the Consolidated Health Economic Evaluation Reporting Standards (CHEERS; for
checklist, see Section J in S1 Text), and base case model parameters are listed in Table 1.

DALYs
For each scenario, we modelled the health burden in DALYs for symptomatic cases, nonfatal
hospitalisations, nonfatal admissions to critical care, and premature death due to COVID-19.
For the nonfatal outcomes, and in the absence of specific DALY data, we used quality-adjusted
life years (QALYs) reported by Sandmann and colleagues [28] based on pandemic influenza
studies treated 1 QALY gained as equivalent to 1 DALY averted.
For COVID-19 deaths, we estimated DALYs, guided by the approach presented by Briggs
and colleagues [29]. We generated age at death in 5-year age bands, and then applied age-specific
life expectancy at death using national life tables for Pakistan (United Nations estimates for 2015
to 2020 [30]). We adjusted years of life lost (YLLs) considering the overall level of disability for
any remaining years of life using data on QoL by age band from Zimbabwe [31] since all other
countries with available data were high-income. However, in our base case analysis, we did not
adjust standard life tables to take into account any reduced life expectancy due to specific comorbidities associated with COVID-19. As a sensitivity analysis, since risk of severe COVID-19 is
higher for people with comorbidities [32], we modelled an alternative scenario in which half of
COVID-19-related deaths were assumed to occur in individuals with higher baseline mortality
(standardised mortality ratio = 1.5) and 10% lower baseline QoL. We calculated the average
DALYs per death using both 3% (base case) and 0% discounting (Table G in S1 Text).

Costs
We estimated annual economic costs of vaccine introduction and of diagnosis and treatment
in 2020 values, using an exchange rate of 155 PKR (Pakistani Rupee) for 1 $ (US dollar) on 1
January 2020 [33] and adjusting earlier data by the gross domestic product (GDP) deflator for
Pakistan [34]. Following WHO guidelines, we used a 3% discount rate for future costs and for
annualising capital investments, while health outcomes are discounted at either 3% (base case)
or 0% [35]. The costing was carried out from a health system (vaccination, testing, and care
and treatment costs) and partial societal perspective (including household costs incurred by
COVID-19 illness and case management or costs of illness, but excluding benefits of reduced
nonpharmaceutical interventions (NPIs)), using a bottom-up ingredients-based approach.
Costs of COVID-19 vaccine introduction. It was assumed that all vaccine doses would
be delivered through campaigns in the community. Vaccine and immunisation costs, including supplies costs per dose with freight charges and wastage, are in Table 1. Full costing details
are given in Sections 6 and 7 in S1 Text.
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The price of the COVID-19 vaccine itself was set at $3 per dose, at which the Serum Institute of India has capped prices for LMICs [36]. The cost per dose of expanding national and
provincial level cold chain equipment was obtained from a model of the costs of delivering
COVID-19 vaccines in the 92 COVAX countries developed by UNICEF [37]. The additional
cold chain costs at the facility level were calculated by allocating a proportion of existing equipment and electricity costs to the COVID-19 vaccine relative to the volume of other vaccines in
the immunisation programme.
We estimated vaccine delivery costs via a statewide campaign by adding together the costs
of human resources, social mobilisation, and transport. We assumed that nurses and vaccinators would deliver the vaccines. We carried out a microcosting of human resource costs using
data from the Disease Control Priorities project [38,39]. Social mobilisation costs were
obtained from budgets from a poliovirus campaign [40]. Transportation costs of delivering
vaccines to the distribution sites were obtained from the UNICEF model [39]. Transportation
costs associated with campaigns originating at facilities were calculated by estimating the
catchment areas for facilities and assuming daily vehicle journeys corresponding to the radius
of the catchment area.
Our delivery costs did not include additional health system activities, such as planning and
coordination, pharmacovigilance, and waste management. Accordingly, we added a 31%
markup on the delivery costs, obtained from the UNICEF model [37].
Costs of COVID-19 diagnosis and treatment. The economic impact of COVID-19 on
the health system includes diagnosis and clinical management. Costing methods and estimates
are reported in full elsewhere [17,43]. Briefly, unit costs of outputs, such as bed days or outpatient visits, were sourced from a range of primary published and unpublished sources in Pakistan. These estimates represent the economic cost of all resources required to deliver health
services, including staff time, capital and equipment, drugs, supplies, and overhead costs.
Quantities of resources used were defined following WHO guidelines and refined based on
expert advice to identify less resource–intensive activities in the area of case management that
were more feasible in low- and middle-income settings. More information on unit costs calculations can be found in Sections G and H in S1 Text.
Household costs of COVID-19 diagnosis and treatment include out-of-pocket expenses for
care seeking, funeral expenses, and productivity losses due to lost income from isolation of
cases and were sourced from previously published work [17].

Outcome evaluation
For our scenarios, we simulate 100 matched replicates sampling from the epidemiological
parameter distribution developed by the fitting process. We calculate the resulting epidemiological and economic outcomes (e.g., cumulative DALYs averted, costs and ICERs at annual
increments after start of vaccination) for each intervention scenario matched to the corresponding nonintervention scenario (i.e., by draw from the parameter distribution). We then
take the relevant quantiles of these simulation outcomes across the samples.

Results
Fit to data and epidemic projections without vaccination
Our transmission model is able to fit reported COVID-19 cases and deaths in Sindh for April
to September 2020 for different infection-induced immunity assumptions; each gives comparable quality fits (deviance information criterion (DIC) values: no waning protection, 2,771;
expected protection 5 years, 2,772; 2.5 years, 2,778; 1 year, 2,766). The model also produces
seropositivity comparable to 3 serosurveys in Karachi. At the end of the fitting period, we
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estimate 48.1K deaths (95% credible interval (CrI): 45.3 to 49.7K) and 10.5M cases (95% CrI:
9.9 to 10.9M), with ascertainment of 5.3% (95% CrI: 4.8% to 5.8%) of deaths and 1.4% (95%
CrI: 1.2% to 2.0%) of cases. Fig 1 shows our baseline assumption of 2.5 years for infectionderived immunity. When the best fitting parameters are used to project cases and deaths
beyond September 2020, however, only the shorter durations of protection appear to give a
reasonable fit (Fig C in S1 Text).
In forward projections of epidemics between 2022 and 2030 in the absence of vaccination,
we found that the duration of immunity following infection is the major determinant of the size
of epidemics, as measured by annual incidence (Fig 2). If immunity largely wanes within a year,
the region will rapidly settle into recurring epidemics of comparable scale to the 2020 waves.
For longer durations of protection, there will tend to be some interannual oscillation. Lifelong
immunity results in transmission only at very low residual levels, though we do not consider
external reintroductions. This is consistent with epidemic theory, where low immunity duration
leads to a rapidly stabilising endemic disease burden, while intermediate durations lead to a
series of shrinking epidemic waves settling eventually to lower endemic transmission.

Impact of vaccination on projected cases and deaths
In our base case scenario, vaccination averts 0.93 (95% Crl: 0.91, 1.0) million cases and 7.3
(95% CrI: 7.2, 7.4) thousand deaths over 10 years (Table 2). We found that the annual cases

Fig 2. Long-term baseline projections without vaccination for different assumptions about the duration of natural immunity. Black line shows median
simulation, and grey windows mark 50 and 95% simulation intervals.
https://doi.org/10.1371/journal.pmed.1003815.g002
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Table 2. Costs in US dollars ($), DALYs averted, cost-effectiveness ratio, cases averted, and deaths averted for different vaccination programme scenarios compared
to a counterfactual scenario without vaccination.
No.

Description

Impact compared to no vaccination
Cases Averted
(millions)

Deaths Averted
(thousands)

Difference in Cost ($
millions)

DALYs Averted
(thousands)

Cost per DALY
Averted ($)

Base case
1

Vaccine base case

0.9 (0.8, 0.9)

10.1 (10.1, 10.3)

2.0 (0.1, 2.9)

70.1 (69.9, 70.6)

27.9 (1.7, 40.9)

0.9 (0.8, 0.9)

10.1 (10.1, 10.3)

2.0 (0.1, 2.9)

97.0 (96.8, 97.3)

20.1 (1.3, 29.5)

54.9 (54.8, 55.4)

35.5 (2.2, 52.2)

Economic assumptions
2

DALYs discounted at 0%

3

DALYs based on higher comorbidities

4

Societal perspective

−20.2 (−22.5, −19.1)

5

$6 price per dose

54.7 (52.8, 55.6)

6

$10 price per dose

124.8 (123.0, 125.8)

70.1 (69.9, 70.6)

cs (cs, cs)
780.5 (749.0, 793.0)
1,781.9 (1,744.2,
1,795.7)

Vaccine and immunity assumptions
7

Target 15+ from outset

1.0 (0.9, 1.0)

6.4 (6.4, 6.5)

2.7 (−1.1, 4.3)

55.9 (55.1, 57.9)

48.4 (cs, 78.0)

8

5-year campaign

6.0 (6.0, 6.0)

40.7 (40.2, 41.3)

85.6 (84.5, 87.3)

344.8 (341.8, 347.7)

248.1 (243.6, 255.1)

9

10-year campaign

10.9 (10.9, 11.0)

67.0 (66.2, 67.9)

270.3 (267.9, 271.8)

560.7 (556.9, 565.5)

482.1 (473.8, 488.1)

10

Slow rollout: 4K courses per day (no
scale-up) for 10 years

0.7 (0.6, 0.7)

32.5 (31.7, 33.5)

38.2 (35.8, 40.1)

154.0 (150.3, 158.5)

247.9 (225.9, 267.1)

11

Fast rollout: 184K courses per day (no
scale-up) for 6 months

3.2 (3.0, 3.3)

20.1 (20.0, 20.2)

102.8 (97.2, 112.4)

181.8 (178.4, 183.2)

565.6 (530.9, 629.5)

12

1-year vaccine and natural immunity
waning

0.9 (0.9, 0.9)

11.9 (11.7, 12.2)

−5.1 (−6.1, −4.7)

81.9 (81.0, 83.8)

cs (cs, cs)

13

5-year vaccine and 2.5-year natural
immunity waning

1.6 (1.6, 1.7)

18.4 (18.2, 18.8)

−53.8 (−54.5, −53.4)

126.8 (125.8, 127.9)

cs (cs, cs)

14

1-dose regimen (twice rate of people
vaccinated)

1.7 (1.6, 1.7)

12.9 (12.9, 13.1)

−48.1 (−53.0, −46.7)

105.8 (104.8, 108.0)

cs (cs, cs)

15

30% vaccine efficacy

0.4 (0.4, 0.4)

5.0 (5.0, 5.1)

36.4 (35.8, 36.9)

33.8 (33.7, 33.9)

1,080.7 (1,056.8,
1,091.2)

16

90% vaccine efficacy

1.1 (1.0, 1.1)

12.2 (12.1, 12.4)

−13.4 (−15.8, −12.3)

85.5 (85.3, 86.2)

cs (cs, cs)

17

Vaccine protects against disease-only

0.6 (0.6, 0.6)

9.1 (8.9, 9.3)

14.2 (13.9, 14.4)

60.1 (59.5, 61.1)

236.8 (227.3, 242.3)

18

Vaccine protection is leaky

0.6 (0.6, 0.7)

8.2 (8.2, 8.3)

18.0 (15.8, 19.3)

55.0 (54.6, 56.0)

327.4 (281.4, 353.4)

The base case vaccination scenario assumes the following: a 1-year campaign using a 2-dose vaccine regimen with 70% efficacy at a price of $3 per dose; 2.5-year
duration of natural and vaccine induced immunity; and costing from a healthcare perspective.
cs, cost saving; DALY, disability-adjusted life year.
https://doi.org/10.1371/journal.pmed.1003815.t002

averted by vaccination are higher for longer duration of vaccine-induced immunity, in scenarios targeting people aged over 15 or over 65 for vaccination (Fig 3). For 70% efficacious vaccines that generated 1, 2.5, and 5 years of protection, the median cumulative cases averted was
negative in 2022, and for vaccines of 1 and 2.5 years of protection, also negative in 2023. Only
duration of immunity of 1 and 2.5 years showed negative deaths averted in 2022 when targeting 15+, and duration of 1 year when targeting 65+.
These temporary negative years are an outcome of delaying a wave of infections (without
replacing lost immunity ongoing vaccination beyond the initial year in the base scenario),
leading to offset epidemic years, which ultimately has some net reduction in cases and deaths,
but in the short-term experiences an epidemic when with no intervention the infectioninduced immunity would be preventing that epidemic. In general, a vaccine with low duration
of immunity delayed and slowed the oscillation of epidemics but does not substantially reduce
total burden because rapid waning leads to relatively low effective coverage.
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Fig 3. Cumulative cases and deaths averted by the end of each year. For a vaccine efficacy of 70%, delivered in a 2-dose schedule over a 1-year vaccine campaign, and
expected duration of infection-derived immunity assumed to be 2.5 years, the median averted disease (lines; darker ribbon 50% IQR, lighter ribbon 95% IQR) with
varying vaccine protection duration (from dark to light, increasing vaccine protection duration) and initial target age group (either 15+ or 65+; after the first quarter of
vaccination, 15+ is targeted in both cases); other scenarios and health outcomes in Figs D and E in S1 Text.
https://doi.org/10.1371/journal.pmed.1003815.g003

Economic outcomes of vaccination strategies
The cost of delivery per dose was estimated to be $1.01, excluding vaccine price, wastage, and
freight charges. Based on a vaccine price of $3 per dose, the total undiscounted cost of the vaccination programme was estimated to be $64.1 million, $496 million, and $1.04 billion for a
1-year, 5-year, and 10-year campaign, respectively.
The incremental cost, taking into account cost savings from reduced COVID-19 burden,
was influenced by the duration of infection-induced immunity (Fig 4). When this duration
was short (1 to 2.5 years), then annual incremental costs are likely to be cost-saving in the long
run. For longer durations of infection-induced immunity, the duration of the campaign
affected the annual incremental costs, with the potential for negative costs at the cessation of
5-year campaigns from a health sector perspective. If the infection-induced immunity is lifelong, then the extra protection from the vaccine is of limited benefit. The cumulative number
of DALYs averted over the entire 10-year time horizon is positive for all vaccine strategies,
although it is especially high for a short duration of natural immunity and long vaccine campaign (Fig 5).

Cost-effectiveness of vaccination scenarios
Over 10 years, our base case vaccination scenario averts 70.1 (95% CrI: 69.9, 70.6) thousand
DALYs, at an additional cost of $2.0 (95% CrI: 0.1, 2.9) million after deducting the cost of the
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Fig 4. Annual incremental costs of vaccination programme (compared to no vaccination) for different vaccination strategies and assumptions about the
duration of infection-induced immunity. Results are shown for vaccination using a 2-dose vaccine regimen with 70% efficacy and 2.5-year duration. The societal
perspective includes household out-of-pocket payments and lost income but excludes wider economic impacts of the pandemic. Red lines show different vaccine
prices, and the solid and dashed lines show health system costs and with societal costs, respectively.
https://doi.org/10.1371/journal.pmed.1003815.g004

vaccination programme (Table 2). These results are relatively stable when vaccination is not
age-targeted (i.e., the entire population 15 years and older are given vaccination from the outset), DALYs are discounted at 0%, or COVID-19 patients are assumed to have a higher rate of
comorbidities.
A 1-dose regimen (assuming no loss in efficacy) with twice the rate of people vaccinated
results in greater health gains averting 105.8 thousand DALYs and is cost saving. Extending
the length of the vaccination campaign to 5 or 10 years also substantially increases health benefits but also leads to higher costs yielding ICERs of $248.1 and $482.1, respectively.
Increasing the vaccine price to $6 or $10 per dose would dramatically increase the net costs,
leading, respectively, to ICERs of $781 or $1,782 per DALY averted. On the other hand, a vaccine with higher efficacy, longer duration of vaccine protection, or using a societal perspective
would make vaccination cost saving.
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Fig 5. Cumulative DALYs averted over the 10-year period due to potential vaccination programmes. For
vaccination using a 2-dose vaccine regimen with 70% efficacy and 2.5-year duration. DALY, disability-adjusted life
year.
https://doi.org/10.1371/journal.pmed.1003815.g005

Discussion
Under a variety of practically relevant epidemiological and economic assumptions, this model
of COVID-19 projects that a vaccine programme consistent with the rollout speed projected
by COVAX can avert millions of cases and tens of thousands of deaths, and do so in a costeffective or even cost-saving manner. The particular context considered, Sindh, is a setting
with a young population, high SARS-CoV-2 transmission in the past, and limited resources.
The age distributions, contact patterns, pandemic history, costs, and income levels of most
LMICs are likely more similar to those used in this analysis than to those in comparable studies
for high-income countries. While the specific quantities found in this analysis are unlikely to
apply explicitly, the qualitative differences from high-income countries likely will.
Reiterating our base case scenario, results: assuming that SARS-CoV-2 does not produce
lifelong infection-induced immunity, reaching the COVAX-proposed level of coverage (20%)
of an efficacious vaccine (70% efficacy for 2.5 years) within a year (and then ceasing vaccination) may avert 900,000 cases and 10,000 deaths.
Under our base case assumptions, a single year of vaccination would cost an additional $2
million compared to no vaccination and would avoid 70,000 DALYs resulting in an ICER of
$28 per DALY averted. This assumes that vaccination can be delivered at $1 a dose, in line
with incremental economic cost estimates from the EPIC vaccine delivery costs catalogue,
which range between $0.48 and $1.38 for new vaccines [44]. A vaccination campaign extended
to 5 years or 10 years would avert substantially more DALYs, but with higher incremental
costs, resulting in ICERs of $248 and $482 per DALY averted, respectively. Pakistan does not
have a fixed cost-effectiveness threshold. However, a recently conducted exercise defining
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Pakistan’s Essential Package of Health Services found that over half of the interventions
included had an ICER higher than $500 per DALY averted [38,39].
This model also indicates that these benefits are not particularly dependent on the age
group targeted. We found that initially prioritising 65+ year olds would avert 60% more
COVID-19 deaths compared to vaccinating everyone 15+ years, although the 2 strategies had
similar cost-effectiveness since the broader strategy would prevent more cases and more deaths
in younger individuals. We did not consider more complex age prioritisation strategies, such
as vaccinating 5-year age bands until reaching a particular coverage and then prioritising the
next lower band, because such a programme would entail more complex administration costs
and need a model validated on age-specific past cases. We do not have the appropriate data to
support such an analysis.
The similarity in economic benefits differs from other model-based analyses set in highincome countries [11–13,28], which find that targeting older adults initially would be much
more cost-effective. Potential reasons for these differences include the younger age structure of
Sindh compared to high-income countries, and the inferred seroprevalence, which was greater
than 50% by September 2020. Initial epidemic waves in Sindh (and other settings) may have
raised population-level immunity to a point where transmission-reducing vaccination in hightransmission subgroups (i.e., younger, working age) can indirectly protect subgroups at high
risk of severe disease (i.e., older, comorbid). While the quantitative benefits decline if the vaccine only provides protection against disease, the conclusions about comparable benefits for
either age prioritisation scheme hold.
However, vaccination would be substantially less cost-effective, and potentially not costeffective from a purely healthcare payer perspective, if the vaccine could only be procured and
delivered at $10 a dose or had efficacy as low as 30%. Also, even if a large-scale multiyear mass
vaccination programme is cost-effective, it may nonetheless drain scarce financial and human
resources from other essential health services. In addition, there are many nonfinancial constraints (e.g., trained personnel), meaning that health opportunity cost may be higher without
careful delivery planning. Decisions about vaccination should also take account of other factors besides cost-effectiveness, such as the disproportionately high burden of COVID-19 and
related interventions on socioeconomically marginalised groups, and the urgent need to return
the economy and society to normal. To effectively inform policy decisions, analyses such as
this should be combined with analyses of macroeconomic impact and data on broader societal
impacts in a transparent decision framework (e.g., health technology assessment).
In general, our epidemiological projections have relatively narrow uncertainty intervals.
While there remains substantial uncertainty on a daily basis, this tends to be offsetting: Cases
may shift a little in time, but an annual aggregation results in fairly narrow estimates. These
relatively small intervals propagate through the rest of the analysis. These narrow intervals are
an accurate reflection of the model assumptions, but the model is fixing many aspects of the
real world that are likely to shift unpredictably over the next several years.
As demonstrated by recent emergence of novel variants, the underlying epidemiology may
shift, as will technological and social trends, including the relative prices of the inputs to the
economic estimation. Variants able to escape vaccine-induced immunity may be introduced
either through importation or local mutation. This process is partially addressed by considering loss of infection- and vaccine-derived immunity. For the fastest immunity loss we considered, expected protection durations of a year, a consistently efficacious vaccine (as might be
produced by annual updates) can still be cost saving. If variant emergence was more rapid,
revaccination with updated formulations might not be able to keep pace, corresponding to
lower efficacy. Lower efficacy vaccine (30%) scenarios for rapid protection loss generally
resulted in much worse costs per DALY averted (order 1,000s of $ per DALY).
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We also assumed that within a particular age group, there is no association between probability of getting vaccinated and risk of disease. This may not be accurate if, e.g., vaccination targets people with comorbidities (and hence higher risk of severe COVID-19 disease), or people
who are risk averse (and hence less likely to be infected) are also more likely to get vaccinated.
We do not consider future NPIs beyond May 2021 or innovative coordination with vaccination. If there are substantial changes from the impacts integrated into the fitted estimates of
local transmission, our projections will not reflect those. Given these core limitations and
uncertainties, the intervals ought to be thought of as about our estimate of the central trend
conditional on the scenarios, rather than as reflecting the total volatility in the system.
We used a range of scenarios for the duration of natural immunity, although the shortest
duration (1 year) best fitted case and death data. This is because the apparent loss of natural
immunity may be driven by other factors we did not consider such as behaviour change or
emergence of escape variants. If natural immunity is indeed short-lived, this will further
strengthen the conclusion that vaccination is likely to be cost saving.
Our findings provide an example of the type of analysis that LMICs can employ to inform
vaccination strategies in terms of target populations and financing requirements. While the
economic and societal impact of COVID-19 is substantial, the real resource constraints within
the health sector in many LMICs mean that vaccination strategies need to balance the current
emergency and the longer term needs of the health sector. The slow rate of vaccine distribution
is the major impediment to a larger health impact. Administering vaccine doses in line with
projected COVAX availability in a province of roughly 50 million people, it would take around
3 years to reach 60% population coverage. Such a long-term programme may not be feasible if
vaccine delivery disrupts delivery of other health services, which is a possibility given that the
vaccine is targeted at an age group outside the usual Expanded Program on Immunization
(EPI). Hence, both short-term rapid response and longer-term consideration about how
COVID-19 vaccination can be incorporated in the broader package of essential health services
are important in Pakistan and beyond.
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